Skip to main content
SRZN
NASDAQ Life Sciences

Major Investor Group's Stake Diluted to 29.3% Following Company Offerings

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$28.15
Mkt Cap
$326.832M
52W Low
$5.9
52W High
$35
52W Position info
377% above low
Off High info
20% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

SRZN has more than doubled off its 52-week low of $5.9.

Summary

The Column Group III, a major investor group including a company director, reported a diluted ownership stake of 29.3% in Surrozen, Inc., reflecting the impact of recent company share issuances.


Key Events · Ownership and Investor Activity · SRZN

  • Major Shareholder Update

    The Column Group III entities, including director Tim Kutzkey, now beneficially own 3,824,612 shares, representing 29.3% of Surrozen's common stock.

  • Dilution from Company Offerings

    The decrease in percentage ownership is attributed to dilution from the company's recent capital raising activities, including a $200 million shelf offering and a $50 million At-The-Market program launched in March 2026.

  • Significant Stake Maintained

    Despite the dilution, the group's holding remains substantial, valued at approximately $107.7 million based on the current stock price.


Analysis · SRZN · Life Sciences

This Schedule 13D/A updates the beneficial ownership of The Column Group III entities, including director Tim Kutzkey, to 29.3% of Surrozen's common stock. The filing explicitly states this percentage decrease is due to dilution from the company's recent sales of additional shares, such as the $200 million shelf offering and $50 million ATM program initiated in March 2026. While the group remains a significant shareholder, their relative influence has been reduced by these capital raises.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SRZN was trading at $28.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $326.8M. The 52-week trading range was $5.90 to $35.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SRZN - Latest Insights

SRZN
Nov 13, 2026, 8:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $32.05
Real-time Price: $31.74 info
Change: -$0.310 (-0.97%) info
Market Cap: $605.017M info
SRZN
Nov 09, 2026, 4:59 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $32.00
Real-time Price: $31.74 info
Change: -$0.260 (-0.81%) info
Market Cap: $605.017M info
SRZN
Nov 09, 2026, 4:18 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $32.00
Real-time Price: $31.74 info
Change: -$0.260 (-0.81%) info
Market Cap: $605.017M info
SRZN
Nov 09, 2026, 4:06 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $32.00
Real-time Price: $31.74 info
Change: -$0.260 (-0.81%) info
Market Cap: $605.017M info
SRZN
Oct 20, 2026, 4:59 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $25.14
Real-time Price: $31.74 info
Change: +$6.60 (+26%) info
Market Cap: $605.017M info